BRNS Barinthus Biotherapeutics plc - American Depositary Shares
$0.65
가격 · 8월 19, 2026
기준 재무 정보 8월 6, 2026
52주 범위
$1–$2
11% of range
애널리스트 평점
BUY
8 analysts
목표 주가
$5
+668% upside
P/E (TTM)
-0.4
ROE
-65.0%
순이익률
—
BRNS 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$0.65
시가총액
$27M
P/E (TTM)
-0.4
EPS (TTM)
$-1.64
매출 (TTM)
$0
배당 수익률
—
ROE
-65.0%
부채/자본
—
52주 범위
$1 – $2
BRNS 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$0
2020-12-31
→
2025-12-31
EPS
$-1.64
2020-12-31
→
2025-12-31
잉여현금흐름
$-48M
2021-12-31
→
2025-12-31
마진
—
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
BRNS
동종업계 중앙값
P/E (TTM)
-0.4
—
P/B
0.4
4.4
Price / FCF (주가 / FCF)
-0.6
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
BRNS
동종업계 중앙값
ROA
-51.4%
-38.9%
ROE
-65.0%
-49.6%
ROIC
-94.8%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
BRNS
동종업계 중앙값
Current Ratio (유동비율)
7.8
10.5
Quick Ratio (당좌 비율)
7.0
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
BRNS
동종업계 중앙값
Revenue YoY (매출 YoY)
1766.5%
—
Revenue CAGR 3Y (매출 CAGR 3년)
282.2%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
BRNS
동종업계 중앙값
BRNS 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
8 명의 애널리스트
- 적극 매수 2 25.0%
- 매수 5 62.5%
- 보유 1 12.5%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
2 명의 애널리스트 · 2026-08-15
중앙값
$5.00
← 모든 목표가 하회
$0.65
저가
$4.00
고가
$6.00
중앙값 목표
$5.00
+668.3%
평균 목표
$5.00
+668.3%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
0.00%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-0.26 | $-0.29 | 0.03% |
| 2026년 3월 31일 | $-0.14 | $-0.29 | 0.15% |
| 2025년 12월 31일 | $-0.27 | $-0.35 | 0.08% |
| 2025년 9월 30일 | $-0.24 | $-0.40 | 0.16% |
| 2025년 6월 30일 | $-0.52 | $-0.34 | -0.18% |
| 2025년 3월 31일 | $-0.49 | $-0.37 | -0.12% |
| 2024년 12월 31일 | $-0.51 | $-0.42 | -0.09% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| BRNS | $29M | -0.4 | 1766.5% | — | -65.0% | — |
| ROIV | $19.95B | -51.3 | -71.6% | -3629.2% | -6.5% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $15M | $802.0K | $45M | $268.0K | $5M | |
| R&D Expense | $26M | $42M | $45M | $42M | $20M | $14M | |
| SG&A Expense | $41M | $30M | $40M | $6M | $25M | $10M | |
| Operating Expenses | $71M | $84M | $85M | $49M | $45M | $25M | |
| Operating Income | $-71M | $-68M | $-84M | $-4M | $-45M | $-20M | |
| Interest Expense | · | · | $28.0K | $19.0K | $3M | $4M | |
| Interest Income | $2M | $3M | $3M | $3M | $2.0K | $0 | |
| Other Non-op | $16.0K | $135.0K | $1M | $567.0K | $332.0K | $42.0K | |
| Pretax Income | $-67M | $-61M | $-77M | $850.0K | $-51M | · | |
| Income Tax | $-175.0K | $-44.0K | $-3M | $-4M | $-28.0K | $95.0K | |
| Net Income | $-66M | $-61M | $-73M | $5M | $-51M | $-18M | |
| EPS (Basic) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-2.24 | |
| EPS (Diluted) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-2.24 | |
| Shares (Basic) | 40,527,218 | 39,348,240 | 38,386,491 | 37,248,126 | 25,894,375 | 7,904,529 | |
| Shares (Diluted) | 40,527,218 | 39,348,240 | 38,386,491 | 38,169,307 | 25,894,375 | 7,904,529 | |
| EBITDA | $-65M | $-62M | $-78M | $282.0K | $-45M | · |
대차대조표 23
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $70M | $111M | $142M | $194M | $214M | $43M | |
| Receivables | · | · | · | $323.0K | $20.0K | $518.0K | |
| Prepaid Expense | $5M | $6M | $10M | $8M | $6M | $1M | |
| Other Current Assets | $115.0K | $344.0K | $1M | $611.0K | $995.0K | $29.0K | |
| Current Assets | $78M | $126M | $157M | $213M | $227M | $48M | |
| PP&E (Net) | $4M | $7M | $12M | $8M | $2M | $629.0K | |
| PP&E (Gross) | $11M | $17M | $16M | $9M | $3M | $1M | |
| Accum. Depreciation | $8M | $9M | $4M | $1M | $886.0K | $479.0K | |
| Goodwill | · | $0 | $12M | $12M | $13M | · | |
| Intangibles | $14M | $22M | $25M | $28M | $31M | · | |
| Total Assets | $98M | $160M | $215M | $270M | $281M | $51M | |
| Accounts Payable | $350.0K | $2M | $2M | $4M | $2M | $5M | |
| Current Liabilities | $10M | $16M | $13M | $12M | $11M | $8M | |
| Capital Leases | $9M | $10M | $11M | $8M | $7M | $1M | |
| Deferred Tax | $254.0K | $438.0K | $574.0K | $13M | $12M | $2M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $965.0K | · | · | |
| Total Liabilities | $24M | $30M | $28M | $27M | $28M | $54M | |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $0 | |
| Paid-in Capital | $394M | $393M | $387M | $380M | $369M | $22M | |
| Retained Earnings | $-304M | $-238M | $-177M | $-103M | $-109M | $-58M | |
| Stockholders' Equity | $74M | $130M | $187M | $243M | $252M | $-37M | |
| Liabilities + Equity | $98M | $160M | $215M | $270M | $281M | $51M | |
| Shares Outstanding | 40,848,893 | 40,234,663 | 38,643,540 | 37,683,531 | 37,188,730 | 7,960,458 |
현금 흐름 15
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $5M | $4M | $602.0K | $208.0K | |
| Stock-based Comp | $468.0K | $5M | $5M | $10M | $16M | $4M | |
| Deferred Tax | $-175.0K | $-44.0K | $-3M | $-4M | $-119.0K | · | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $200.0K | $0 | |
| Other Non-cash | $12M | $22M | $15M | $-30M | $1M | · | |
| Operating Cash Flow | $-48M | $-29M | $-51M | $-14M | $-33M | $-11M | |
| CapEx | $37.0K | $892.0K | $5M | $6M | $1M | $293.0K | |
| Investing Cash Flow | $416.0K | $-892.0K | $-5M | $-6M | $-13M | $-293.0K | |
| Stock Issued | $0 | $2M | $2M | $484.0K | $103M | · | |
| Net Stock Activity | $0 | $2M | $2M | $484.0K | $103M | · | |
| Financing Cash Flow | $2.0K | $2M | $2M | $325.0K | $223M | $41M | |
| Net Change in Cash | $-41M | $-30M | $-52M | $-20M | $171M | $32M | |
| Taxes Paid | · | · | $0 | $0 | $152.0K | · | |
| Free Cash Flow | $-48M | $-30M | $-56M | $-21M | $-34M | · | |
| Levered FCF | · | · | $-56M | $-21M | · | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | -454.1% | -10463.1% | -9.0% | -16873.5% | · | |
| Net Margin | · | -408.0% | -9145.5% | 11.9% | -18979.5% | · | |
| Pretax Margin | · | -409.0% | -9541.4% | 1.9% | · | · | |
| EBITDA Margin | · | -415.3% | -9786.2% | 0.63% | -16648.9% | · | |
| ROA | -51.4% | -32.6% | -30.3% | 1.9% | -30.7% | · | |
| ROE | -65.0% | -38.6% | -34.1% | 2.2% | -20.2% | · | |
| ROIC | -94.8% | -52.2% | -43.1% | -10.4% | · | · |
유동성 및 지급능력 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 7.8 | 8.0 | 12.5 | 17.4 | 20.3 | · | |
| Quick Ratio | 7.0 | 7.1 | 11.3 | 15.9 | 19.2 | · | |
| Interest Coverage | · | · | -2996.9 | -212.7 | -16.9 | · |
효율성 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.0 | 0.2 | 0.0 | · | |
| Receivables Turnover | · | · | · | 260.7 | 1.0 | · |
성장률 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | 1766.5% | -98.2% | 16580.2% | -94.4% | · | |
| Revenue CAGR 3Y | · | 282.2% | -45.0% | · | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $15M | $802.0K | $45M | $268.0K | · | |
| Net Income TTM | $-66M | $-61M | $-73M | $5M | $-51M | · | |
| Market Cap | $29M | $49M | $143M | $89M | $413M | · | |
| P/E | -0.4 | -0.8 | -1.9 | 16.8 | -5.7 | · | |
| P/S | · | 3.2 | 177.8 | 2.0 | 1541.7 | · | |
| P/B | 0.4 | 0.4 | 0.8 | 0.4 | 1.6 | · | |
| P / Tangible Book | 0.5 | 0.4 | 1.0 | 0.4 | 2.0 | · | |
| P / Cash Flow | -0.6 | -1.7 | -2.8 | -6.1 | -12.7 | · | |
| P / FCF | -0.6 | -1.6 | -2.5 | -4.3 | -12.2 | · | |
| Earnings Yield | -234.3% | -128.3% | -51.8% | 6.0% | -17.6% | · |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $0 | · | · | $0 | $15M | $0 | $0 | $0 | $0 | $334.0K | $468.0K | $6M | $6M | |
| R&D Expense | $4M | $4M | $4M | $5M | $8M | $8M | $8M | $11M | $12M | $11M | $6M | $15M | $14M | $10M | $12M | $10M | |
| SG&A Expense | $7M | $3M | $8M | $5M | $15M | $13M | $3M | $13M | $7M | $6M | $14M | $961.0K | $13M | $12M | · | · | |
| Operating Expenses | $11M | $6M | $12M | $15M | $23M | $21M | $24M | $25M | $19M | $17M | $20M | $16M | $27M | $22M | $32M | $-1M | |
| Operating Income | $-11M | $-6M | $-12M | $-15M | $-23M | $-21M | $-23M | $-9M | $-18M | $-17M | $-20M | $-16M | $-26M | $-21M | $-25M | $7M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $12.0K | · | $7.0K | $14.0K | $0 | · | · | |
| Interest Income | $343.0K | $350.0K | $406.0K | $472.0K | $523.0K | $556.0K | $637.0K | $631.0K | $635.0K | $775.0K | $571.0K | $196.0K | $522.0K | $2M | $1M | $1M | |
| Other Non-op | $26.0K | $39.0K | $-104.0K | $-275.0K | $320.0K | $75.0K | $89.0K | $26.0K | $20.0K | $0 | $-2M | $-2.0K | $310.0K | $3M | $516.0K | $0 | |
| Pretax Income | $-11M | $-6M | $-11M | $-15M | $-21M | $-20M | $-21M | $-8M | $-17M | $-16M | $-18M | $-15M | $-25M | $-19M | $-23M | $8M | |
| Income Tax | $-23.0K | $-16.0K | $-57.0K | $-71.0K | $-25.0K | $-22.0K | $3.0K | $-3.0K | $-7.0K | $-37.0K | $-820.0K | $-603.0K | $-1M | $-516.0K | $-2M | $-674.0K | |
| Net Income | $-11M | $-6M | $-11M | $-15M | $-21M | $-20M | $-21M | $-8M | $-17M | $-15M | $-17M | $-14M | $-24M | $-18M | $-21M | $8M | |
| EPS (Basic) | $-0.26 | $-0.14 | $-0.27 | $-0.36 | $-0.52 | $-0.49 | $-0.51 | $-0.21 | $-0.43 | $-0.40 | $-0.44 | $-0.37 | $-0.62 | $-0.48 | $-0.57 | $0.22 | |
| EPS (Diluted) | $-0.26 | $-0.14 | $-0.27 | $-0.36 | $-0.52 | $-0.49 | $-0.51 | $-0.21 | $-0.43 | $-0.40 | $-0.44 | $-0.37 | $-0.62 | $-0.48 | $-0.56 | $0.22 | |
| Shares (Basic) | 40,848,893 | 40,848,893 | -80,742,637 | 40,661,118 | 40,343,521 | 40,265,216 | -77,885,800 | 39,419,447 | 39,041,111 | 38,773,482 | -76,568,413 | 38,533,833 | 38,407,672 | 38,013,399 | -74,392,619 | 37,247,123 | |
| Shares (Diluted) | 40,848,893 | 40,848,893 | -80,742,637 | 40,661,118 | 40,343,521 | 40,265,216 | -77,885,800 | 39,419,447 | 39,041,111 | 38,773,482 | -76,568,413 | 38,533,833 | 38,407,672 | 38,013,399 | -76,508,351 | 38,156,564 | |
| EBITDA | $-11M | $-5M | · | $-15M | $-23M | $-19M | · | $-9M | $-18M | $-15M | · | $-16M | $-26M | $-20M | · | $8M |
대차대조표 23
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $59M | $66M | $70M | $74M | $86M | $99M | $111M | · | · | · | $142M | $160M | $173M | $191M | $194M | $200M | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | · | · | $172.0K | · | $26.0K | |
| Prepaid Expense | $2M | $4M | $5M | $6M | $8M | $6M | $6M | $8M | $10M | $8M | $10M | $7M | $8M | $6M | $8M | $8M | |
| Other Current Assets | $151.0K | $194.0K | $115.0K | $663.0K | $854.0K | $435.0K | $344.0K | $464.0K | $626.0K | $2M | $1M | $355.0K | $1M | $549.0K | $611.0K | $130.0K | |
| Current Assets | $63M | $73M | $78M | $87M | $100M | $110M | $126M | $135M | $132M | $143M | $157M | $171M | $185M | $201M | $213M | $219M | |
| PP&E (Net) | $3M | $3M | $4M | $5M | $5M | $6M | $7M | $11M | $11M | $12M | $12M | $12M | $14M | $13M | $8M | $7M | |
| PP&E (Gross) | · | · | $11M | · | · | · | $17M | · | · | · | $16M | · | · | · | $9M | · | |
| Accum. Depreciation | · | · | $8M | · | · | · | $9M | · | · | · | $4M | · | · | · | $1M | · | |
| Goodwill | · | · | · | · | · | · | · | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $13M | |
| Intangibles | $13M | $14M | $14M | $15M | $20M | $21M | $22M | $23M | $24M | $24M | $25M | $26M | $27M | $27M | $28M | $29M | |
| Total Assets | $82M | $92M | $98M | $109M | $130M | $142M | $160M | $189M | $187M | $199M | $215M | $230M | $246M | $262M | $270M | $275M | |
| Accounts Payable | $535.0K | $993.0K | $350.0K | $698.0K | $2M | $1M | $2M | $3M | $3M | $1M | $2M | $5M | $2M | $4M | $4M | $2M | |
| Current Liabilities | $11M | $12M | $10M | $11M | $13M | $12M | $16M | $15M | $16M | $13M | $13M | $19M | $12M | $12M | $12M | $14M | |
| Capital Leases | $9M | $9M | $9M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | $11M | $11M | $11M | $10M | $8M | $8M | |
| Deferred Tax | $215.0K | $237.0K | $254.0K | $320.0K | $391.0K | $416.0K | $438.0K | $457.0K | · | · | $574.0K | · | · | · | $13M | · | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $965.0K | $711.0K | |
| Total Liabilities | $25M | $26M | $24M | $25M | $27M | $26M | $30M | $29M | $30M | $27M | $28M | $34M | $29M | $28M | $27M | $31M | |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Paid-in Capital | $395M | $394M | $394M | $393M | $394M | $394M | $393M | $392M | $390M | $389M | $387M | $386M | $386M | $384M | $380M | $377M | |
| Retained Earnings | $-320M | $-310M | $-304M | $-293M | $-278M | $-257M | $-238M | $-217M | $-209M | $-192M | $-177M | $-159M | $-145M | $-121M | $-103M | $-82M | |
| Stockholders' Equity | $57M | $66M | $74M | $84M | $102M | $115M | $130M | $159M | $157M | $172M | $187M | $195M | $217M | $233M | $243M | $244M | |
| Liabilities + Equity | $82M | $92M | $98M | $109M | $130M | $142M | $160M | $189M | $187M | $199M | $215M | $230M | $246M | $262M | $270M | $275M | |
| Shares Outstanding | 40,848,893 | 40,848,893 | 40,848,893 | 40,827,263 | 40,348,665 | 40,339,395 | 40,234,663 | 39,542,518 | 39,184,338 | 38,952,956 | 38,643,540 | 38,546,594 | 38,524,059 | 38,357,025 | 37,683,531 | 37,291,492 |
현금 흐름 15
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $820.0K | $856.0K | $909.0K | $901.0K | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Stock-based Comp | $433.0K | $556.0K | $696.0K | $-415.0K | $-281.0K | $468.0K | $755.0K | $1M | $1M | $2M | $786.0K | $57.0K | $2M | $2M | $2M | $1M | |
| Deferred Tax | $-23.0K | $-16.0K | $-57.0K | $-71.0K | $-25.0K | $-22.0K | $3.0K | $-3.0K | $-7.0K | $-37.0K | $-821.0K | $-602.0K | $-1M | $-516.0K | $-2M | $-625.0K | |
| Amort. of Intangibles | $600.0K | $600.0K | $600.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | $800.0K | |
| Other Non-cash | · | $769.0K | · | · | · | $2M | · | · | · | $659.0K | · | · | · | $12M | · | · | |
| Operating Cash Flow | $-8M | $-3M | $-4M | $-11M | $-18M | $-15M | $13M | $-18M | $-12M | $-12M | $-20M | $-11M | $-17M | $-3M | $-11M | $12M | |
| CapEx | $0 | $0 | $0 | $0 | $32.0K | $5.0K | $278.0K | $114.0K | $192.0K | $308.0K | $-153.0K | $36.0K | $3M | $3M | $586.0K | $2M | |
| Investing Cash Flow | $61.0K | $55.0K | $2.0K | $451.0K | $-32.0K | $-5.0K | $-278.0K | $-114.0K | $-192.0K | $-308.0K | $153.0K | $-36.0K | $-3M | $-3M | $-586.0K | $-2M | |
| Stock Issued | · | · | $0 | $0 | $0 | $0 | $837.0K | $465.0K | $358.0K | $503.0K | $109.0K | $46.0K | $91.0K | $2M | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $503.0K | · | · | · | $2M | · | · | |
| Financing Cash Flow | $0 | $0 | $0 | $0 | $0 | $2.0K | $837.0K | $465.0K | $358.0K | $503.0K | $109.0K | $46.0K | $28.0K | $2M | $484.0K | $0 | |
| Net Change in Cash | $-8M | $-5M | $-4M | $-12M | $-13M | $-12M | $6M | $-12M | $-12M | $-12M | $-18M | $-13M | $-18M | $-3M | $-6M | $8M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $0 | $0 | · | |
| Free Cash Flow | · | $-3M | · | · | · | $-15M | · | · | · | $-12M | · | · | · | $-6M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-12M | · | · | · | · | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | -62.7% | · | · | · | 230071.4% | -7885.3% | -4590.6% | · | 122.5% | |
| Net Margin | · | · | · | · | · | · | · | -54.2% | · | · | · | 201028.6% | -7126.3% | -3884.6% | · | 133.7% | |
| Pretax Margin | · | · | · | · | · | · | · | -54.3% | · | · | · | 210185.7% | -7473.1% | -4004.1% | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | -62.7% | · | · | · | 230071.4% | -7885.3% | -4329.7% | · | 122.5% | |
| ROA | -10.0% | -4.7% | · | -9.8% | -13.4% | -11.5% | · | -3.9% | -7.8% | -6.7% | · | -5.6% | -9.0% | -6.6% | · | 3.1% | |
| ROE | -13.3% | -6.1% | · | -11.9% | -16.3% | -13.7% | · | -4.6% | -9.1% | -7.6% | · | -6.4% | -10.1% | -7.5% | · | 3.4% | |
| ROIC | -19.3% | -9.1% | · | -17.8% | -22.8% | -17.8% | · | -5.9% | -11.7% | -9.8% | · | -7.9% | -11.6% | -9.0% | · | · |
유동성 및 지급능력 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.5 | 6.1 | · | 8.0 | 7.9 | 9.2 | · | 8.9 | 8.5 | 11.2 | · | 9.2 | 15.3 | 16.7 | · | 15.6 | |
| Quick Ratio | 5.2 | 5.5 | · | 6.9 | 6.8 | 8.3 | · | · | · | · | · | 8.6 | 14.3 | 16.0 | · | 14.3 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1409.5 | · | · | · | · | · | · |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | · | · | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.1 | · | 181.3 |
가치 평가 (TTM) 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | $15M | $15M | · | $15M | $334.0K | $802.0K | · | $7M | $24M | $39M | · | $38M | |
| Net Income TTM | $-52M | $-61M | · | $-63M | $-66M | $-60M | · | $-55M | $-70M | $-72M | · | $-48M | $-18M | $8M | · | $22M | |
| Market Cap | $27M | $23M | · | $51M | $38M | $39M | · | $47M | $55M | $93M | · | $119M | $79M | $86M | · | $119M | |
| P/E | -0.5 | -0.4 | · | -0.8 | -0.6 | -0.6 | · | -0.8 | -0.8 | -1.3 | · | -2.5 | -4.4 | 10.3 | · | 5.6 | |
| P/S | · | · | · | · | 2.5 | 2.6 | · | 3.1 | 164.2 | 115.6 | · | 17.1 | 3.3 | 2.2 | · | 3.1 | |
| P/B | 0.5 | 0.4 | · | 0.6 | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.5 | |
| P / Tangible Book | 0.6 | 0.4 | · | 0.7 | 0.5 | 0.4 | · | 0.4 | 0.5 | 0.7 | · | 0.8 | 0.4 | 0.4 | · | 0.6 | |
| P / Cash Flow | · | -6.9 | · | · | · | -2.6 | · | · | · | -7.8 | · | · | · | -27.1 | · | · | |
| P / FCF | · | -6.9 | · | · | · | -2.6 | · | · | · | -7.6 | · | · | · | -15.1 | · | · | |
| Earnings Yield | -193.9% | -265.4% | · | -126.4% | -177.4% | -157.2% | · | -118.5% | -130.0% | -78.6% | · | -40.5% | -22.8% | 9.7% | · | 17.8% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $0 | $15M | $802.0K | $45M | $268.0K |
| 영업이익률 % | — | -454.1% | -10463.1% | -9.0% | -16873.5% |
| 순이익 | $-66M | $-61M | $-73M | $5M | $-51M |
| 희석 EPS | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 7.8 | 8.0 | 12.5 | 17.4 | 20.3 |
| 당좌 비율 | 7.0 | 7.1 | 11.3 | 15.9 | 19.2 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-48M | $-30M | $-56M | $-21M | $-34M |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 15개의 제출자 · $7.8M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 3 (+1 이전 분기 대비) | 2 (+1 이전 분기 대비) | 2 (-1 이전 분기 대비) | 2 (+2 이전 분기 대비) | -92K |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| M&G PLC | $5,197,349 | 5,197,349 | 66.28% | 주식 |
| HSG Holding Ltd | $937,512 | 1,420,473 | 11.96% | 주식 |
| GLR Partners, LLC | $820,629 | 1,243,377 | 10.47% | 주식 |
| DC Funds, LP | $423,855 | 642,204 | 5.41% | 주식 |
| Rangeley Capital, LLC | $122,190 | 185,136 | 1.56% | 주식 |
| Johns Hopkins University | $80,676 | 122,237 | 1.03% | 주식 |
| MORGAN STANLEY | $71,782 | 108,760 | 0.92% | 주식 |
| Baird Financial Group, Inc. | $69,934 | 105,961 | 0.89% | 주식 |
| CITADEL ADVISORS LLC | $50,658 | 76,754 | 0.65% | 주식 |
| HighTower Advisors, LLC | $24,717 | 37,450 | 0.32% | 주식 |
| RENAISSANCE TECHNOLOGIES LLC | $16,500 | 25,000 | 0.21% | 주식 |
| XTX Topco Ltd | $9,781 | 14,819 | 0.12% | 주식 |
| RHUMBLINE ADVISERS | $7,712 | 11,685 | 0.10% | 주식 |
| TWO SIGMA SECURITIES, LLC | $7,294 | 11,052 | 0.09% | 주식 |
| UBS Group AG | $665 | 1,008 | 0.01% | 주식 |
회사 내부자 16 명의 내부자 · 9 임원 · 7 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| William Enright | Chief Executive Officer | 2024년 1월 2일 A | 728,454 | 0 | 0 | $0 |
| Gemma Brown | Chief Financial Officer | 2024년 1월 2일 A | — | 0 | 0 | $0 |
| Georgy Egorov | Chief Financial Officer | 2022년 1월 3일 A | — | 0 | 0 | $0 |
| Christopher Ellis | Chief Operating Officer | 2023년 1월 3일 A | 75 | 0 | 0 | $0 |
| Leon Hooftman | Chief Medical Officer | 2024년 6월 3일 A | — | 0 | 0 | $0 |
| Nadege Pelletier | Chief Scientific Officer | 2024년 1월 2일 A | — | 0 | 0 | $0 |
| Graham Griffiths | Chief Business Officer | 2024년 1월 2일 A | 104,209 | 0 | 0 | $0 |
| Thomas George Evans | Fmr Chief Scientific Officer | 2023년 1월 3일 A | — | 0 | 0 | $0 |
| Margaret Marshall | Chief Medical Officer | 2023년 1월 3일 A | — | 0 | 0 | $0 |
| Joseph Scheeren | 이사 | 2023년 6월 26일 P | 23,000 | 0 | 0 | $0 |
| Robin Wright | 이사 | 2023년 5월 25일 P | 48,256 | 0 | 0 | $0 |
| Pierre A. Morgon | 이사 | 2023년 5월 11일 A | — | 0 | 0 | $0 |
| Alex Hammacher | 이사 | 2023년 5월 11일 A | 3,000 | 0 | 0 | $0 |
| Anne M. Phillips | 이사 | 2023년 5월 11일 A | 3,000 | 0 | 0 | $0 |
| Karen A Dawes | 이사 | 2023년 5월 11일 A | 1,700 | 0 | 0 | $0 |
| Oxford Sciences Innovation plc | 10% 소유주 | 2021년 5월 4일 C | 8,797,770 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 1 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| International Generosity Foundation Trust | 2026년 4월 13일 | 6.70% | 최초 제출 | 수동적 투자 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.